1. The cyclin-like protein, SPY1, regulates the ERα and ERK1/2 pathways promoting tamoxifen resistance
   Rosa-Maria Ferraiuolo et al, 2017, Oncotarget CrossRef
2. Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)—PathIES
   Zsolt Szijgyarto et al, 2019, Breast Cancer Research and Treatment CrossRef
3. The Tumor Microenvironment as a Regulator of Endocrine Resistance in Breast Cancer
   María Inés Diaz Bessone et al, 2019, Frontiers in Endocrinology CrossRef
4. Glyphosate mimics 17β-estradiol effects promoting estrogen receptor alpha activity in breast cancer cells
   Juan P. Muñoz et al, 2023, Chemosphere CrossRef
5. MST2 silencing induces apoptosis and inhibits tumor growth for estrogen receptor alpha-positive MCF-7 breast cancer
   Joonwoo Park et al, 2020, Toxicology and Applied Pharmacology CrossRef
6. IGF-1 Receptor Modulates FoxO1-Mediated Tamoxifen Response in Breast Cancer Cells
   Ali Vaziri-Gohar et al, 2017, Molecular Cancer Research CrossRef
7. Targeting CDK7 reverses tamoxifen resistance through regulating stemness in ER+ breast cancer
   Yasmin M. Attia et al, 2022, Pharmacological Reports CrossRef
8. Conditional expression of Ki-RasG12V in the mammary epithelium of transgenic mice induces estrogen receptor alpha (ERα)-positive adenocarcinoma
   S Andò et al, 2017, Oncogene CrossRef
9. Blockade of CDK7 Reverses Endocrine Therapy Resistance in Breast Cancer
   Yasmin M. Attia et al, 2020, International Journal of Molecular Sciences CrossRef
10. IL6 induces TAM resistance via kinase-specific phosphorylation of ERα in OVCA cells
    Yue Wang et al, 2015, Journal of Molecular Endocrinology CrossRef
11. Integrated molecular analysis of Tamoxifen-resistant invasive lobular breast cancer cells identifies MAPK and GRM/mGluR signaling as therapeutic vulnerabilities
    Hillary Stires et al, 2018, Molecular and Cellular Endocrinology CrossRef
12. Molecular markers associated with the outcome of tamoxifen treatment in estrogen receptor-positive breast cancer patients: scoping review and in silico analysis
    Maiquidieli Dal Berto et al, 2021, Discover Oncology CrossRef
13. Linc-RoR promotes MAPK/ERK signaling and confers estrogen-independent growth of breast cancer
    Wan-xin Peng et al, 2017, Molecular Cancer CrossRef
14. The estrogen receptor-alpha S118P variant does not affect breast cancer incidence or response to endocrine therapies
    Berry Button et al, 2019, Breast Cancer Research and Treatment CrossRef
15. Endocrine Resistance in Breast Cancer: The Role of Estrogen Receptor Stability
    Sarah A. Jeffreys et al, 2020, Cells CrossRef
16. Circadian and Melatonin Disruption by Exposure to Light at Night Drives Intrinsic Resistance to Tamoxifen Therapy in Breast Cancer
    Robert T. Dauchy et al, 2014, Cancer Research CrossRef
17. Feedback control of the CXCR7/CXCL11 chemokine axis by estrogen receptor α in ovarian cancer
    Samira Benhadjeba et al, 2018, Molecular Oncology CrossRef
18. Ceramide synthase 4 overexpression exerts oncogenic properties in breast cancer
    Su-Jeong Kim et al, 2023, Lipids in Health and Disease CrossRef
19. Overexpression of BQ323636.1 Modulated AR/IL-8/CXCR1 Axis to Confer Tamoxifen Resistance in ER-Positive Breast Cancer
    Ho Tsoi et al, 2022, Life CrossRef
20. Sox2 promotes tamoxifen resistance in breast cancer cells
    Marco Piva et al, 2014, EMBO Molecular Medicine CrossRef
21. CDK7 in breast cancer: mechanisms of action and therapeutic potential
    Ying Gong et al, 2024, Cell Communication and Signaling CrossRef
22. Obesity and endocrine therapy resistance in breast cancer: Mechanistic insights and perspectives
    Ines Barone et al, 2022, Obesity Reviews CrossRef
23. Estrogen receptor alpha phosphorylation and its functional impact in human breast cancer
    Muralidharan Anbalagan et al, 2015, Molecular and Cellular Endocrinology CrossRef